Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Vividion gets $82mm via Series B financing

Executive Summary

Vividion Therapeutics Inc. (proteomic drug discovery) raised $82mm in an oversubscribed Series B financing led by first-time backer Nextech Invest, which adds a board member and was joined by other new investors BVF Partners, Casdin Capital, Mubadala Ventures, Trinitas Capital, Mirae Asset Capital, Altitude Life Science Ventures, and Alexandria Venture Investments, and returning shareholders Arch Venture Partners, Versant Ventures, Cardinal Partners, and partner Celgene. The company’s platform is based on work performed at Scripps Research Institute, from which Vividion spun off in 2014. The IP enables the screening of small molecules against all proteins and identifies highly selective binders to previously intractable targets. Series B proceeds will help move lead programs into the clinic and expand the company's early-stage pipeline. The firm is initially focusing on the areas of cancer and immunology.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies